
Targeted Prodrug Chemotherapy For Prostate CancerAward last edited on: 6/29/10
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$159,988Award Phase
1Solicitation Topic Code
-----Principal Investigator
Jenny C WuCompany Information
Acaduceus Pharmaceutics Inc
11171 Bubb Road
Cupertino, CA 95014
Cupertino, CA 95014
(408) 306-5635 |
jennywu@acaduceuspharma.com |
www.acaduceuspharma.com |
Location: Single
Congr. District: 18
County: Santa Clara
Congr. District: 18
County: Santa Clara
Phase I
Contract Number: 1R43CA139677-01A1Start Date: 00/00/00 Completed: 00/00/00
Phase I year
2009Phase I Amount
$159,988Public Health Relevance:
We will develop the novel prodrugs: DOX-PSASP-BBN-RGD for the targeted chemotherapy of prostate cancer. The new prodrugs have a highly potent cytotoxic agent, a heterodimer of two peptides specific for prostate cancer receptors and different cleavable linkers for targeted chemotherapy of prostate cancers. Because the prodrugs targets preferentially to specific receptors on cancer cells, we anticipated that the new prodrugs will have better efficacy and reduced peripheral toxicity. The same strategy should also be applicable to other cancer therapeutics.
Public Health Relevance Statement:
We will develop the novel prodrugs: DOX-PSASP-BBN-RGD for the targeted chemotherapy of prostate cancer. The new prodrugs have a highly potent cytotoxic agent, a heterodimer of two peptides specific for prostate cancer receptors and different cleavable linkers for targeted chemotherapy of prostate cancers. Because the prodrugs targets preferentially to specific receptors on cancer cells, we anticipated that the new prodrugs will have better efficacy and reduced peripheral toxicity. The same strategy should also be applicable to other cancer therapeutics.
NIH Spending Category:
Aging; Cancer; Prostate Cancer; Urologic Diseases
Project Terms:
(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione; 14-Hydroxydaunomycin; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; Adriamycine; Adverse effects; Affinity; Androgenic Agents; Androgenic Compounds; Androgens; Apoptosis; Apoptosis Pathway; Arg-Gly-Asp; Arginine-Glycine-Aspartic Acid Cell Adhesion Domain; Binding; Binding (Molecular Function); Biodistribution; Blood Serum; Bombesin Receptor; Bystander Effect; Cancer Model; Cancer Treatment; Cancer of Prostate; CancerModel; Cancers; Cell Death; Cell Death, Programmed; Cell surface; Cells; Chemotherapy Protocol; Chemotherapy Regimen; Chemotherapy, Cancer, General; Chemotherapy-Oncologic Procedure; Cleaved cell; Clinical; Clinical Protocols; Clinical Trials, Phase I; Clinical Trials, Phase II; Combination Chemotherapy Regimen; Coupling; Cytotoxic agent; Cytotoxic drug; DOX; Data Reporting; Definitive Radiation Therapy; Detection; Diagnosis; Disease; Disorder; Dose-Limiting; Doxorubicin; Doxorubicina; Drug Delivery; Drug Delivery Systems; Drug Formulations; Drug Kinetics; Drug Precursors; Drug Targeting; Drug Targetings; Drugs; EBRT; EC 3.4.21.34; Early-Stage Clinical Trials; Endocrine Therapy; Endothelial Cells; Enzymes; Evaluation; External Beam RT; External Beam Radiation Therapy; External Radiation; Extracellular Matrix, Integrins; F element; Figs; Figs - dietary; Fletcher Factor; Fluorine; Formulation; Formulations, Drug; Goals; Hormonal Therapy; Hydrolysis; Hydroxyl Daunorubicin; Hydroxyldaunorubicin; Image; Imaging Procedures; Imaging Techniques; In Vitro; Industry; Integrins; KLK3; Kallikrein 3; Killings; Kinetic; Kinetics; Label; Lead; Libraries; Lytotoxicity; Malignant Cell; Malignant Neoplasm Therapy; Malignant Neoplasm Treatment; Malignant Neoplasms; Malignant Tumor; Malignant Tumor of the Prostate; Malignant neoplasm of prostate; Malignant prostatic tumor; Mammals, Mice; Maximal Tolerated Dose; Maximally Tolerated Dose; Maximum Tolerated Dose; Medical Imaging, Positron Emission Tomography; Medication; Metastasis; Metastasize; Metastatic Neoplasm; Metastatic Tumor; Methods; Mice; Molecular Interaction; Molecular Target; Monitor; Murine; Mus; NMBR; Neoplasm Metastasis; Operation; Operative Procedures; Operative Surgical Procedures; P-30 Antigen; PET; PET Scan; PET imaging; PETSCAN; PETT; Parents; Patients; Pb element; Peptides; Peripheral; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmaceutics; Pharmacodynamics; Pharmacokinetics; Pharmacologic Substance; Pharmacological Substance; Pharmacy (field); Phase; Phase 1 Clinical Trials; Phase 2 Clinical Trials; Phase I Clinical Trials; Phase I Study; Phase II Clinical Trials; Plasma Kallikrein Precursor; Plasma Prekallikrein; Positron Emission Tomography Scan; Positron-Emission Tomography; Pro-Drugs; Prodrugs; Production; Programs (PT); Programs [Publication Type]; Prostate CA; Prostate Cancer; Prostate Specific Antigen Preproprotein; Prostate-Specific Antigen; Prostatic Cancer; Proteins; Proton Magnetic Resonance Spectroscopic Imaging; Quimioterapia; RGD; RGD (peptide); RGD (sequence); RGD Cell Adhesion Domain; RGD Domain; RGD Motif; RGD Tripeptide Sequence; RGD tripeptide; Rad.-PET; Radiation; Radioactive; Receptor Protein; Receptors, Gastrin-Releasing Peptide; Receptors, Neuromedin B; Recurrence; Recurrent; SBIR; SBIRS (R43/44); Secondary Neoplasm; Secondary Tumor; Secondary to; Seed Implant; Seed Implantation; Semenogelase; Seminin; Serum; Small Business Innovation Research; Small Business Innovation Research Grant; Specificity; Staging; Stromal Cells; Structure; Surgical; Surgical Interventions; Surgical Procedure; Survival Rate; System; System, LOINC Axis 4; Technics, Imaging; Testing; Therapeutic; Therapeutic Androgen; Toxic effect; Toxicities; Treatment Efficacy; Treatment Side Effects; Tumor Cell; Tumor Cell Migration; Xenograft Model; advanced disease; androgen independent prostate cancer; anticancer therapy; arginyl-glycyl-aspartic acid; base; cancer cell; cancer chemotherapy; cancer metastasis; cancer therapy; cancer type; chemotherapeutic agent; chemotherapy; cleaved; cytotoxic; cytotoxicity; density; design; designing; disease/disorder; drug/agent; effective therapy; experience; experiment; experimental research; experimental study; external-beam radiation; gamma-Seminoprotein; gene product; hK3 Kallikrein; heavy metal Pb; heavy metal lead; hormone therapy; hydrophilicity; imaging; immunopathology; in vivo; innovate; innovation; innovative; kininogenin; malignancy; men; men's; molecular imaging; multimodality; necrocytosis; neoplasm/cancer; neoplastic cell; new approaches; novel; novel approaches; novel strategies; novel strategy; phase 1 study; phase 1 trial; phase 2 study; phase 2 trial; phase I trial; phase II trial; preclinical safety; programs; protocol, phase I; protocol, phase II; public health relevance; ray (radiation); receptor; receptor binding; research study; response; side effect; study, phase II; surgery; therapeutic efficacy; therapeutic target; therapeutically effective; therapy adverse effect; treatment adverse effect; treatment effect; treatment strategy; tumor; uptake
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00